DaVita Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Javier J. Rodriguez
- Full Time Employees
- 78,000
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- Address
- 2000 16th Street Denver CO United States of America 80202
- IPO Date
- Oct 31, 1995
- CIK
- 0000927066
- Website
- davita.com
- Similar Companies
- Business
- DaVita Inc. DaVita Inc. provides kidney care services, primarily dialysis treatments for patients with chronic kidney failure and end-stage kidney disease; operates approximately 2,675 outpatient dialysis centers in the United States serving more than 200,000 patients and 367 centers in 11 other countries serving around 49,400 patients; offers related laboratory services, including routine tests for dialysis patients and other physician-prescribed tests; delivers home-based hemodialysis, hospital inpatient dialysis, and acute inpatient dialysis services; provides integrated kidney care and disease management through DaVita Integrated Kidney Care for risk-based arrangements; conducts clinical research via DaVita Clinical Research since 1985 across pharmaceutical and medical device development; supports nephrologists with technology solutions through DaVita Physician Solutions; and develops innovative health care solutions for kidney disease patients through DaVita Venture Group. The company, incorporated in 1994 and formerly known as DaVita HealthCare Partners Inc. until a 2016 name change, maintains world headquarters in Denver, Colorado, and generates the majority of revenues from Medicare and government-based programs while targeting commercial payers for higher margins; it holds a 37% share of the U.S. dialysis market and operates internationally across regions including Latin America, Europe, and Asia. DaVita Inc. recently expanded internationally through 2024 acquisitions from Fresenius Medical Care for $300 million, adding over 270 clinics in Brazil, Colombia, Chile, and Ecuador to become Latin America's largest dialysis provider; entered new markets in Ecuador and Chile while deepening presence in Colombia; refinanced debt with a new $1.9 billion Term Loan B-2 and $3.5 billion credit facilities including a $2 billion Term Loan A-2 and $1.5 billion revolving facility in 2025; issued $1 billion in senior notes due 2033; and reported Q3 2025 revenues of $3.42 billion amid volume challenges from flu season, Hurricane Helene, and a cyber incident.
Company News
DaVita Brings New Clinical Research to ASN Kidney Week 2026, Advancing Evidence for the Next Era of Kidney Care
Why DaVita HealthCare (DVA) Outpaced the Stock Market Today
DaVita: After A 25% Drop, The Buyback Machine Is Cheap Again
Here's Why You Should Retain DaVita Stock in Your Portfolio for Now
DaVita Activates Emergency Response Efforts Ahead of Hurricane Isaias, Urges Kidney Patients to Prepare Early
3 Berkshire Hathaway Holdings to Buy While They Sit at Least 15% Below Their Highs
DaVita HealthCare (DVA) Laps the Stock Market: Here's Why
This Warren Buffett Stock Is Up 58%. History Says This Is What Happens Next.
DaVita HealthCare (DVA) Registers a Bigger Fall Than the Market: Important Facts to Note
3 Surging Stocks That Don't Need the AI Boom to Keep Winning
DaVita HealthCare (DVA) Advances While Market Declines: Some Information for Investors
Warren Buffett, Donald Trump Bet on Same 17 Stocks — Some Might Surprise You
A Look at DaVita Inc (DVA) After 4.3% Gain -- GF Value $195.67 vs Price $189.32
Here's Why You Should Retain DaVita Stock in Your Portfolio for Now
Why Is DaVita HealthCare (DVA) Down 4.9% Since Last Earnings Report?
Do Options Traders Know Something About DaVita Stock We Don't?
4 Outpatient & Home Healthcare Stocks in Focus Amid Industry Tailwinds
Warren Buffett and Greg Abel Quietly Hold a Bigger Percentage of This Company Than Any Other in Berkshire's Portfolio (Hint: It's Not Apple or American Express)
DVA & Humana Expand Value-Based Care for Kidney Disease Patients
Alebund Pharmaceuticals Announces 2026 Interim Results